CANCER GENE THERAPY USING CYTOKINE AND CHEMOKINE GENES

Access this Article

Author(s)

    • Mukaida Naofumi
    • Division of Molecular Bioregulation, Cancer Research Institute Kanazawa University

Abstract

Surgical or radiotherapy-mediated eradication of tumors gives the best opportunity for cure, if the tumor is restricted to the primary sites. Chemotherapy is employed for disseminated disease but frequently fails to give clinical benefit. Thus, with our ever expanding understanding of the regulatory mechanisms of cytokine- and/or chemokine-mediated immune reactions to tumor, these molecules have become good candidates for cancer therapy. Unfortunately, most cytokines and chemokines have very short half-lives and their systemic delivery of pharmacological doses frequently results in severe adverse effects. These circumstances prompted many investigators to evaluate the genetic delivery of cytokines and chemokines for the treatment of cancer. Here, current status of clinical and pre-clinical studies of cytokine and chemokines will be discussed, particularly focusing on those with clinical relevance.

Journal

  • Annals of Cancer Research and Therapy

    Annals of Cancer Research and Therapy 12(1/2), 33-51, 2004

    The Japanese Society of Strategies for Cancer Research and Therapy

Codes

  • NII Article ID (NAID)
    130000120347
  • Text Lang
    ENG
  • ISSN
    1344-6835
  • Data Source
    J-STAGE 
Page Top